U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H26N2O4
Molecular Weight 406.4742
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARVEDILOL

SMILES

COC1=C(OCCNCC(O)COC2=CC=CC3=C2C4=C(N3)C=CC=C4)C=CC=C1

InChI

InChIKey=OGHNVEJMJSYVRP-UHFFFAOYSA-N
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3

HIDE SMILES / InChI
Molecular Formula C24H26N2O4
Molecular Weight 406.4742
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Carvedilol competitively blocks β1, β2 and α1 receptors. The drug lacks sympathomimetic activity and has vasodilating properties that are exerted primarily through α1-blockade. Animal models indicate that carvedilol confers protection against myocardial necrosis, arrhythmia and cell damage caused by oxidising free radicals, and the drug has no adverse effects on plasma lipid profiles. COREG® (carvedilol) is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol is the first drug of its kind to be approved for the treatment of congestive heart failure, and is now the standard of care for this devastating disease. Carvedilol is also confirmed as effective in the management of mild to moderate hypertension and ischaemic heart disease.

CNS Activity

Originator

Boehringer Mannheim
18
Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/carvedilol.html

Approval Year

1995
186
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2760
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
COREG

Approved Use

COREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure). COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Launch Date

8.1103677E11
Primary
Approved
8360
COREG

Approved Use

COREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure). COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Launch Date

8.1103677E11
Primary
Approved
8360
COREG

Approved Use

COREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure). COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Launch Date

8.1103677E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.4 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10934668
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL, (+)- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
8.46 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10934668
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL, (-)- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
26.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10934668
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
94.3 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10934668
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL, (+)- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
42.2 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10934668
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL, (-)- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
139 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10934668
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Co-administed with::
lorazepam(7 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31988787
unknown, 41 years
n = 1
Health Status: unknown
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/31988787
Other AEs: Wheezing...
Other AEs:
Wheezing (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31988787
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22240593
unhealthy, 66.7±12.0 years
n = 7
Health Status: unhealthy
Condition: chronic heart failure
Age Group: 66.7±12.0 years
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/22240593
Sources:
https://pubmed.ncbi.nlm.nih.gov/22240593
375 mg single, oral
Overdose
Dose: 375 mg
Route: oral
Route: single
Dose: 375 mg
Co-administed with::
simvastatin(fifteen 20-mg tablets)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18598302
unhealthy, 84 years
n = 1
Health Status: unhealthy
Age Group: 84 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18598302
Other AEs: Hypotension...
Other AEs:
Hypotension (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18598302
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
unhealthy, adult
n = 765
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Population Size: 765
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
Disc. AE: Hypotension...
AEs leading to
discontinuation/dose reduction:
Hypotension (0.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
Disc. AE: Congestive cardiac failure...
AEs leading to
discontinuation/dose reduction:
Congestive cardiac failure (moderate, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
25 mg 2 times / day steady, oral
Dose: 25 mg, 2 times / day
Route: oral
Route: steady
Dose: 25 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
unhealthy, adult
n = 1156
Health Status: unhealthy
Condition: severe heart failure
Age Group: adult
Population Size: 1156
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
Disc. AE: Dizziness...
AEs leading to
discontinuation/dose reduction:
Dizziness (1.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
6.25 mg 2 times / day multiple, oral
Dose: 6.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6.25 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
Disc. AE: Abdominal distension...
AEs leading to
discontinuation/dose reduction:
Abdominal distension (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
6.25 mg 2 times / day multiple, oral
Dose: 6.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6.25 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (moderate, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
AEs

AEs

AESignificanceDosePopulation
Wheezing 1 patient
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Co-administed with::
lorazepam(7 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31988787
unknown, 41 years
n = 1
Health Status: unknown
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/31988787
Hypotension 1 patient
375 mg single, oral
Overdose
Dose: 375 mg
Route: oral
Route: single
Dose: 375 mg
Co-administed with::
simvastatin(fifteen 20-mg tablets)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18598302
unhealthy, 84 years
n = 1
Health Status: unhealthy
Age Group: 84 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18598302
Hypotension 0.7%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
unhealthy, adult
n = 765
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Population Size: 765
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
Congestive cardiac failure moderate, 1 patient
Disc. AE
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
Dizziness 1.3%
Disc. AE
25 mg 2 times / day steady, oral
Dose: 25 mg, 2 times / day
Route: oral
Route: steady
Dose: 25 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
unhealthy, adult
n = 1156
Health Status: unhealthy
Condition: severe heart failure
Age Group: adult
Population Size: 1156
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
Abdominal distension 1 patient
Disc. AE
6.25 mg 2 times / day multiple, oral
Dose: 6.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6.25 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
Rash moderate, 1 patient
Disc. AE
6.25 mg 2 times / day multiple, oral
Dose: 6.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6.25 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf
Page: p. 61
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3441
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3441
ChemicalBook
CB8351959
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8351959
MolPort
MolPort-003-666-814
https://www.molport.com/shop/molecule-link/MolPort-003-666-814
Selleck Chemicals
carvedilol
http://www.selleckchem.com/products/carvedilol.html
eMolecules
901524
https://www.emolecules.com/cgi-bin/more?vid=901524
PubMed

PubMed

TitleDatePubMed
Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
1999 Dec 1
Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart.
2000
Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.
2000 Apr
Carvedilol affects the physiological and behavioral response to smoked cocaine in humans.
2000 Jul 1
Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells.
2000 Nov
Comitogenic effect of catecholamines on rat cardiac fibroblasts in culture.
2000 Nov
Levosimendan.
2001
CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI.
2001 Apr
Carvedilol as therapy in pediatric heart failure: an initial multicenter experience.
2001 Apr
Carvedilol--a new dimension in pediatric heart failure therapy.
2001 Apr
50th Annual scientific sessions of the American college of cardiology.
2001 Apr 10
Development of a capillary electrophoresis assay for the determination of carvedilol enantiomers in serum using cyclodextrins.
2001 Feb
Variceal bleeding and portal hypertension: still a therapeutic challenge?
2001 Feb
Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes.
2001 Feb 1
Antiarrhythmic drug carvedilol inhibits HERG potassium channels.
2001 Feb 1
Inhibitory effect of carvedilol in the high-conductance state of the mitochondrial permeability transition pore.
2001 Feb 2
Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study.
2001 Feb 27
Impressive amelioration of clinical (NYHA class) and echocardiographic parameters in heart failure patients treated with amiodarone and carvedilol.
2001 Jan
A placebo controlled evaluation of the antifibrillatory effects of carvedilol.
2001 Jan
beta(1)-Adrenoceptors compensate for beta(3)-adrenoceptors in ileum from beta(3)-adrenoceptor knock-out mice.
2001 Jan
Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228.
2001 Jan 15
Effect of carvedilol on atrioventricular conduction in the ischemic heart.
2001 Jan 26
[Effects of carvedilol in rats with induced chronic kidney failure].
2001 Jan-Feb
Effects of carvedilol on left ventricular function, mass, and scintigraphic findings in isolated left ventricular non-compaction.
2001 Jul
Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts.
2001 Jul
Stereoselective effects of (R)- and (S)-carvedilol in humans.
2001 Jul
Using isoproterenol stress echocardiography to predict the response to carvedilol in patients with dilated cardiomyopathy.
2001 Jun
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
2001 Jun
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
2001 Jun
Differing beta-blocking effects of carvedilol and metoprolol.
2001 Jun
Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment.
2001 Jun
Protective effect of carvedilol on chenodeoxycholate induction of the permeability transition pore.
2001 Jun 1
Beta-blocker trials seem to be in conflict.
2001 Jun 12
Beta-blockade in chronic heart failure.
2001 Jun 12
Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy.
2001 Jun 15
Nebivolol, carvedilol and metoprolol do not influence cardiac Ca(2+) sensitivity.
2001 Jun 22
Random research.
2001 Jun 26
[Options in drug combinations].
2001 Mar
[Adrenergic beta inhibitors in heart insufficiency: which and when?].
2001 Mar
Determination of carvedilol in human cardiac tissue by high-performance liquid chromatography.
2001 Mar
[Severe heart failure. Carvedilol lowers mortality].
2001 Mar 1
What is the optimal medical management of ischemic heart failure?
2001 Mar-Apr
Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial.
2001 May
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
2001 May
Carvedilol in the treatment of chronic heart failure.
2001 May
Carvedilol versus other beta-blockers in heart failure.
2001 May
Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.
2001 May 22
Effect of carvedilol on survival in severe chronic heart failure.
2001 May 31
Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence.
2001 May 5
Economic impact of beta blockade in heart failure.
2001 May 7
Patents

Patents

07605274
6
JP2002541233A
397
JP2004534031A
5
JP2005516940A
28
JP2011510954A
142
US4503067
5

Sample Use Guides

In Vivo Use Guide
Take with food. Individualize dosage and monitor during up-titration.• Heart failure: Start at 3.125 mg twice daily and increase to 6.25, 12.5, and then 25 mg twice daily over intervals of at least 2 weeks. Maintain lower doses if higher doses are not tolerated.• Left ventricular dysfunction following myocardial infarction: Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily afterintervals of 3 to 10 days. A lower starting dose or slower titration may be used.• Hypertension: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg then 25 mg twice daily over intervals of 1 to 2 weeks.
Route of Administration: Oral
In Vitro Use Guide
Compared with the PDGF-stimulated control, DNA synthesis decreased significantly to 60.3% +/- 10.4% and 18.3% +/- 5.9% in the presence of 1 and 10 microM of carvedilol, respectively (P < 0.05, each). Carvedilol significantly inhibited the activity of VSMCs stimulated by ET-1 and ANG-II. The IC50 of carvedilol was 1-10 microM. CsA only inhibited VSMCs significantly in the PDGF-stimulated subgroup. The addition of CsA in the presence of carvedilol did not affect the inhibitory activity of carvedilol. The pattern of inhibition in the combined group was uniform and similar to that of the carvedilol alone group, regardless of the stimulator used.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:29:36 UTC 2023
Edited
by admin
on Wed Jul 05 22:29:36 UTC 2023
Record UNII
0K47UL67F2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARVEDILOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
CARVEDILOL [VANDF]
Common Name English
CARVEDILOL [USAN]
Common Name English
BM-14.190
Code English
NSC-758694
Code English
KREDEX
Brand Name English
2-PROPANOL, 1-(9H-CARBAZOL-4-YLOXY)-3-((2-(2-METHOXYPHENOXY)ETHYL)AMINO)-, (±)-
Systematic Name English
TALLITON
Common Name English
CARVEDILOL [MI]
Common Name English
CARVEDILOL [ORANGE BOOK]
Common Name English
CORONIS
Common Name English
BM 14.190
Code English
DILATREND
Brand Name English
Carvedilol [WHO-DD]
Common Name English
C07AG02
Code English
CARVEDILOL [MART.]
Common Name English
SKF-105517
Code English
COREG
Brand Name English
1-(CARBAZOL-4-YLOXY)-3-((2-(O-METHOXY-PHENOXY)ETHYL)AMINO)-2-PROPANOL
Common Name English
KORVASAN
Common Name English
CARVEDILOL [HSDB]
Common Name English
DQ-2466
Code English
CARVEDILOL [EP MONOGRAPH]
Common Name English
ARTIST
Brand Name English
DIMITONE
Brand Name English
CARVEDILOL [JAN]
Common Name English
EUCARDIC
Brand Name English
CARVEDILOL [USP-RS]
Common Name English
BM-14190
Code English
BM-14-190
Code English
SK&F-105517
Code English
QUERTO
Brand Name English
(±)-1-CARBAZOL-4-YLOXY)-3-((2-(O-METHOXYPHENOXY)ETHYL)AMINO)-2-PROPANOL
Common Name English
carvedilol [INN]
Common Name English
CARVEDILOL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NDF-RT N0000009923
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
NDF-RT N0000175556
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
WHO-ATC C07FX06
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
LIVERTOX NBK548399
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
NDF-RT N0000175553
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
WHO-VATC QC07AG02
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
NDF-RT N0000009924
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
NCI_THESAURUS C29576
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
WHO-ATC C07AG02
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
NDF-RT N0000000099
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL723
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
EPA CompTox
DTXSID8022747
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
DAILYMED
0K47UL67F2
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
RS_ITEM_NUM
1096622
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
PRIMARY
MESH
C043211
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
NCI_THESAURUS
C28906
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
PRIMARY
DRUG BANK
DB01136
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
LACTMED
Carvedilol
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
DRUG CENTRAL
522
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
JAPANESE REVIEW
ARTIST
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY APPROVED AUGUST 2015
RXCUI
20352
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
PRIMARY RxNorm
EVMPD
SUB06153MIG
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
IUPHAR
551
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
NSC
758694
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
PRIMARY
MERCK INDEX
M3143
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY Merck Index
FDA UNII
0K47UL67F2
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
HSDB
7044
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
USAN
Z-25
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
PRIMARY
WIKIPEDIA
Carvedilol
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
PRIMARY
PUBCHEM
2585
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
PRIMARY
INN
5333
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
CAS
72956-09-3
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
CHEBI
3441
Created by admin on Wed Jul 05 22:29:36 UTC 2023 , Edited by admin on Wed Jul 05 22:29:36 UTC 2023
PRIMARY
SMS_ID
100000092577
Created by admin on Wed Jul 05 22:29:37 UTC 2023 , Edited by admin on Wed Jul 05 22:29:37 UTC 2023
PRIMARY
Related Record Type Details
Structure of CARVEDILOL PHOSPHATE
SALT/SOLVATE -> PARENT
Structure of CARVEDILOL PHOSPHATE MONOHYDRATE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Structure of CARVEDILOL, (+)-
ENANTIOMER -> RACEMATE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
MAJOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
Structure of CARVEDILOL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BETA-1 ADRENERGIC RECEPTOR
TARGET -> INHIBITOR
OCT-2
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2E1
METABOLIC ENZYME -> SUBSTRATE
Structure of CARVEDILOL, (-)-
ENANTIOMER -> RACEMATE
Structure of CARVEDILOL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BETA-1 ADRENERGIC RECEPTOR
TARGET -> AGONIST
Structure of CARVEDILOL HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of O-DESMETHYLCARVEDILOL
METABOLITE ACTIVE -> PARENT
PLASMA
Structure of CARVEDILOL GLUCURONIDE
METABOLITE -> PARENT
MAJOR
URINE
Structure of 4-HYDROXYCARVEDILOL
METABOLITE ACTIVE -> PARENT
Structure of 4-HYDROXYCARVEDILOL
METABOLITE ACTIVE -> PARENT
Related Record Type Details
Structure of 2-(2-METHOXYPHENOXY)ETHYL AMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1-(4-(2-HYDROXY-3-(2-(2-METHOXYPHENOXY)ETHYLAMINO)PROPOXY)-9H-CARBAZOL-9-YL)-3-(2-(2-METHOXYPHENOXY)ETHYLAMINO) PROPAN-2-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1-(9H-CARBAZOL-4-YLOXY)-3-(4-(2-HYDROXY-3-((2-(2-METHOXYPHENOXY)ETHYL)AMINO)PROPOXY)-9H-CARBAZOL-9-YL)PROPAN-2-OL
IMPURITY -> PARENT
Structure of 1-(4-(2-HYDROXY-3-(2-(2-METHOXYPHENOXY)ETHYLAMINO)PROPOXY)-9H-CARBAZOL-9-YL)-3-(2-(2-METHOXYPHENOXY)ETHYLAMINO) PROPAN-2-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 4-OXIRANYLMETHOXY-9H-CARBAZOLE
IMPURITY -> PARENT
Structure of N-BENZYLCARVEDILOL
IMPURITY -> PARENT
Structure of 4-OXIRANYLMETHOXY-9H-CARBAZOLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-BENZYLCARVEDILOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-METHYL CARVEDILOL
IMPURITY -> PARENT
Structure of 3,3'-(((1,2-PHENYLENEBIS(OXY))BIS(ETHANE-2,1-DIYL))BIS(AZANEDIYL))BIS(1-((9H-CARBAZOL-4-YL)OXY)PROPAN-2-OL)
IMPURITY -> PARENT
Structure of 1-(9H-CARBAZOL-4-YLOXY)-3-(4-(2-HYDROXY-3-((2-(2-METHOXYPHENOXY)ETHYL)AMINO)PROPOXY)-9H-CARBAZOL-9-YL)PROPAN-2-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-Isopropyl Carvedilol
IMPURITY -> PARENT
Structure of 2-(2-METHOXYPHENOXY)ETHYL AMINE
IMPURITY -> PARENT
Structure of 3,3'-(2-(2-METHOXYPHENOXY)ETHYLAZANEDIYL)BIS(1-(9H-CARBAZOL-4-YLOXY)PROPAN-2-OL)
IMPURITY -> PARENT
Structure of N-BENZYLCARVEDILOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 1-(4-(2-HYDROXY-3-(2-(2-METHOXYPHENOXY)ETHYLAMINO)PROPOXY)-9H-CARBAZOL-9-YL)-3-(2-(2-METHOXYPHENOXY)ETHYLAMINO) PROPAN-2-OL
IMPURITY -> PARENT
Related Record Type Details
Structure of CARVEDILOL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY HEART FAILURE, MORE THAN 85 kg

HEART FAILURE, LESS THAN 85 kg

Volume of Distribution PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966